Research programme: prostate cancer therapeutics - Panacea PharmaceuticalsAlternative Names: PAN-127
Latest Information Update: 29 Jun 2011
At a glance
- Originator Panacea Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 31 May 2010 Preclinical trials in Prostate cancer in USA (unspecified route)